What’s the Latest on COVID-19? - Midwest Region

Faculty

Daniel Kaul, MD
Professor of Internal Medicine
Director, Transplant Infectious Disease
Program Director ID Fellowship Program
University of Michigan
Ann Arbor, Michigan

Raymund R. Razonable, MD, FIDSA, FAST
Professor of Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Target Audience

The educational design of this activity addresses the needs of infectious disease specialists, internal medicine physicians, transplant specialists, oncologist, pharmacists, and other clinicians involved in managing patients who are at heightened risk for poor COVID-19 outcomes.

Educational Objectives 

After completing this activity, the participant should be better able to:

• Discuss recent trial data and current regulatory status for anti-SARS-CoV-2 monoclonal antibodies
• Identify candidates for pre-exposure prophylaxis or treatment with anti-SARS-CoV-2 monoclonal antibodies, including immunocompromised patients
• Create proactive plans with patients, other clinicians, and healthcare systems to ensure prompt and equitable use of anti-SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis or treatment

Program Description

The presence of multiple new COVID-19 variants and subvariants has rapidly shifted strategies for treatment and prevention. Clinicians struggle to remain up to date with a rapidly changing field that has remained a public health concern, including guidelines, Emergency Use Authorization status, and challenges with logistical implementation. In this on-demand webcast, regional faculty will present data on and discuss current evidence and regulatory status for anti-SARS-CoV-2 monoclonal antibodies for treatment and prevention and available antivirals for treatment, updates to National Institutes of Health guidelines on patient identification, and strategies to reduce health care disparities.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

^{*This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.}

Physician Credit Designation

Global designates this other/blended (live and short-term archive) activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.1 hour(s) of pharmacology).

Disclosures of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated.

Daniel Kaul, MD: Contracted Research: Gilead Sciences, Inc.; Nobelpharma Co., Ltd., Takeda Pharmaceutical Company

Raymund R. Razonable, MD, FIDSA, FAST: Contracted Research: Gilead Sciences, Inc. (funds to institution), F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc.; Honoraria: Member of DSMB for Novartis Pharmaceuticals Corporation

The following planners and managers have no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Lauren Sinclair, Gena Dolson, MS, Elizabeth Manheim, PhD, Jim Kappler, PhD

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% or higher on the posttest and complete the program evaluation.

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.